[PDF] Top 20 The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
Has 10000 "The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency" found on our website. Below are the top 20 most common "The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency".
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
... that weekly intravenous Prolastin therapy provides protective levels of circulating AAT protein and it is a well-tolerated and safe ...within 1 week of augmentation therapy, ... See full document
10
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
... usual therapy for COPD there is no certainty that disease progression will continue, particularly in patients with no other recognised risk factors for progression ...the deficiency should be ... See full document
9
Hereditary alpha-1-antitrypsin deficiency and its clinical consequences
... Alpha-1-antitrypsin deficiency (AATD) is a genetic disorder that manifests as pulmonary emphysema, liver cirrhosis and, rarely, as the skin disease panniculitis, and is characterized by low ... See full document
9
Alpha-1 antitrypsin deficiency: outstanding questions and future directions
... The patients were randomised into augmentation therapy or placebo and followed for two years by CT ...the patients received active treatment and were followed for an additional two years ... See full document
15
<p>Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life</p>
... on augmentation therapy to normalize AAT levels and transplantation ...18 Augmentation therapy is not a covered bene fi t ...augmentation therapy. Belgium stopped reimbursement ... See full document
6
Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency
... AATD patients who underwent ECT. Our results suggest that ECT in AATD patients might be associated with a decrease in hyperinflation, an improve- ment in quality of life, and an acceptable safety profile at ... See full document
5
<p>Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population</p>
... COSYCONET patients (the German COPD and SYstemic consequences-COmorbidities NETwork) have also shown a signi fi cantly lower preva- lence of cardiovascular comorbidities in AAT-de fi cient patients with COPD ... See full document
8
Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank
... inflammatory effects of treatment with favorable effects over potential reversible processes such us bronchoconstriction and/or the use of different spirometry ...of patients receiving ... See full document
10
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review
... dosed weekly throughout the ...received augmentation therapy (as opposed to sometimes or always) when FEV 1 ,50% predicted ...between augmentation therapy groups. FEV 1 ... See full document
14
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
... side effects were reported, the most common ones being headache (47%), dizziness (17%), nausea (9%), and dyspnea (9%), the latter being classified as ...receiving weekly treatments did report a higher rate ... See full document
12
Alpha-1 Antitrypsin Deficiency Presenting with MPO-ANCA Associated Vasculitis and Aortic Dissection
... Involvement of large vessels is uncommon in AAV, while extracranial GCA has been commonly observed in patients with cranial GCA [7]. In this patient with a type B aortic dissection and recent MPO-AAV, a more ... See full document
5
Pulmonary abnormalities in intermediate alpha 1 antitrypsin deficiency
... 'Abbreviations used in this paper: AAT, alpha-l-antitrypsin; COPD, chronic obstructive pulmonary disease; Pi, protease inhibitor; R3, R9, RR, total pulmonary resistance by oscillometric [r] ... See full document
10
Alpha 1 antitrypsin deficiency, emphysema, and liver disease Genetic basis and strategies for therapy
... Whereas all are associated with a risk for emphysema to some degree, only mutations causing intracellular accumulation of the newly synthesized alAT are associated with a risk for liver [r] ... See full document
11
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
... replacement therapy on emphysema progression. During RAPID-RCT, patients receiving active therapy achieved statistically significant reductions in the annual loss of lung tissue as compared with ... See full document
14
The prevalence of alpha 1 antitrypsin deficiency in Ireland
... The SERPINA1 gene is highly pleiomorphic with over 100 alleles identified to date [9]. Mutations which confer an increased risk of developing pulmonary emphysema and/or liver disease are those in which deficiency ... See full document
7
Assessment of Alpha-1 Antitrypsin Deficiency in Patients with Severe Chronic Obstructive Pulmonary Disease
... COPD patients, their results confirm finding no shortage of this ...ATT deficiency in COPD patients has been reported to be between ...of patients studied in our study and hence we recommend ... See full document
9
Alternative transcripts of the SERPINA1 gene in alpha 1 antitrypsin deficiency
... AAT is expressed mainly by hepatocytes [9] although other cell types, including monocytes, macrophages, intestinal epithelial cells or cornea, also express this pro- tein [12, 22–25]. The level of plasma AAT is ... See full document
11
Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
... new patients were diagnosed with COPD per year between 2007 and 2012, a figure well above the 375 mean number of COPD patients tested yearly for AATD during the 4 years of our ...the deficiency has ... See full document
6
Deficiency of α-1-antitrypsin influences systemic iron homeostasis
... Figure 4 Plasma metal concentrations among MM, MZ, and ZZ cohorts. Aluminum and iron concentrations were observed to increase in ZZ individuals relative to those with MM and MZ genotype (A). In contrast, copper levels ... See full document
7
Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis
... α 1 -antitrypsin homozygote involving both loss-of-function and gain-of-function ...α 1 -antitrypsin (due to reduced secretion, reduced antiprotease activity, and the polymerization of Z α ... See full document
15
Related subjects